Every Form 4 that Neuropace, Inc. (NPCE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NPCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NPCE filings page.
NeuroPace Inc Chief Medical Officer Martha Morrell reported 335 shares withheld by the issuer on September 24, 2026, to satisfy tax withholding obligations tied to vesting of a restricted stock unit award. The reported per-share price was $13.97, and her reported direct holdings after the transaction were 51,357 shares. No Rule 10b5-1 plan is reported.
NeuroPace Inc (NPCE) reported that Chief Financial Officer Patrick F. Williams had 1,162 shares of common stock withheld on September 20, 2026 to satisfy tax withholding obligations upon the vesting of a restricted stock unit award. This code F transaction was not an open-market sale, and 67,508 shares of common stock remained held directly afterward.
NeuroPace Inc (NPCE) reported that Chief Executive Officer and director Joel Becker had 1,310 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations arising from the vesting of a restricted stock unit award. After this tax-withholding disposition, he holds 138,000 shares of NeuroPace common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
NeuroPace Inc (NPCE) reported an insider tax-withholding transaction by Chief Executive Officer and director Joel Becker. On August 27, 2026, 1,126 shares of common stock were withheld by NeuroPace to satisfy tax withholding obligations arising from the vesting of a restricted stock unit award. Following this withholding transaction, Becker directly held 139,310 shares of NeuroPace common stock.
NeuroPace Inc (NPCE) reported an insider equity withholding transaction by Chief Medical Officer Martha Morrell. On August 27, 2026, 358 shares of common stock were withheld by the company at $14.13 per share to cover tax withholding obligations related to the vesting of a restricted stock unit award. After this withholding, Morrell directly held 51,692 shares of NeuroPace common stock.
NeuroPace Inc’s Chief Medical Officer, Martha Morrell, reported a routine share withholding for taxes. On June 24, 2026, 335 shares of common stock were disposed of at $16.22 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this tax-withholding transaction, she directly holds 52,050 shares of NeuroPace common stock.
NeuroPace director Uri Geiger received a stock award of 789 shares of common stock at $15.63 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, so this is a routine compensation-related acquisition rather than an open-market purchase.
After this award, Geiger holds 18,537 NeuroPace shares directly. Separately, 4,432,948 shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power via his role at Accelmed Partners II, LLC.
Fischer Frank M reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Frank M. Fischer received 1,467 shares of Common Stock on June 19, 2026. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, bringing his directly held stake to 599,534 shares.
Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Rakhi Kumar received a stock grant of 989 common shares, valued at $15.63 per share, as part of non-employee director compensation in lieu of quarterly cash retainer fees. Following this award, Kumar directly holds a total of 23,039 NeuroPace common shares.
NeuroPace Inc director R Scott Huennekens received new equity awards as compensation. He was granted 2,890 shares of Common Stock and a stock option for 5,368 shares at an exercise price of $15.74 per share.
The 2,890 shares will vest in twelve equal monthly installments, and the 5,368 option shares will also vest in twelve equal monthly installments, in each case conditioned on his continuous service through each vesting date. Following these awards, he holds 2,890 Common shares and 5,368 option shares directly.
NeuroPace Inc director Frank M. Fischer received equity compensation consisting of common stock and stock options. He was granted 2,890 shares of common stock at no cost, increasing his direct holdings to 598,067 shares. He was also granted options for 5,368 shares at an exercise price of $15.74 per share, expiring on June 4, 2036.
Both the shares and options vest in twelve equal monthly installments, contingent on his continuous service, which makes this a scheduled, compensation-related award rather than a market purchase or sale.
NeuroPace Inc director Uri Geiger reported new equity awards and updated holdings. He received a grant of 2,890 shares of common stock at no cost, bringing his directly held common shares to 17,748. These shares vest in twelve equal monthly installments, subject to his continuous service.
Geiger was also granted stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, expiring in 2036, which likewise vest in twelve equal monthly installments while he remains in service. Separately, 4,432,948 common shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power.
NeuroPace Inc director Rakhi Kumar received new equity awards. On the reported date, Kumar was granted 2,890 shares of common stock at no purchase price, increasing direct holdings to 22,050 shares.
Kumar was also granted stock options for 5,368 shares of common stock at an exercise price of $15.74, expiring in 2036. Both the stock and option grants vest in twelve equal monthly installments, contingent on continued service through each vesting date.
NeuroPace Inc director Renee Ryan received new equity awards as part of compensation. She was granted 2,890 shares of common stock at no cost, bringing her direct common stock holdings to 2,890 shares after the transaction.
She also received stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, with 5,368 options held after the grant. Both the share grant and the options vest in twelve equal consecutive monthly installments, conditioned on her continuous service through each vesting date, and the options expire on June 4, 2036.
NeuroPace Inc director Lisa Andrade received new equity compensation consisting of common shares and stock options. She was granted 2,890 shares of Common Stock at no cost, all held directly. Following this grant, she directly owns 2,890 common shares.
She was also granted a Stock Option for 5,368 shares of Common Stock at an exercise price of $15.74 per share, expiring on June 4, 2036. Both the shares and the option vest in twelve equal monthly installments, contingent on her continuous service through each vesting date.
NeuroPace Inc director and CEO Joel Becker reported a routine share disposition tied to equity compensation. On June 3, 2026, 1,255 shares of common stock were withheld by the company at $15.88 per share to cover tax obligations from a restricted stock unit vesting. After this tax-withholding event, Becker directly holds 140,436 shares of NeuroPace common stock.
NeuroPace Inc director and CEO Joel Becker had 1,126 shares of Common Stock withheld on May 27, 2026 to cover taxes from a restricted stock unit vesting. This was a tax-withholding disposition by the company rather than an open-market sale.
Following the withholding, Becker directly holds 141,691 shares of NeuroPace Common Stock. The transaction reflects routine tax treatment of equity compensation and does not represent a discretionary buy or sell decision in the market.
NeuroPace Inc chief medical officer Martha Morrell reported a routine tax-withholding transaction related to equity compensation. On May 27, 2026, 358 shares of common stock were withheld by the company to cover tax obligations triggered by the vesting of a restricted stock unit award. This was not an open-market sale. After this withholding, she directly held 52,385 shares of NeuroPace common stock.
NeuroPace Inc Chief Financial Officer Patrick F. Williams reported equity compensation awards consisting of restricted stock units and stock options. He received 16,820 shares of Common Stock as a grant, taking his directly held Common Stock to 68,670 shares after the award.
The grant is in the form of RSUs, each representing one share of common stock upon settlement, with 25% vesting on May 15, 2027 and the remainder vesting in 12 equal quarterly installments thereafter. He was also granted stock options for 44,800 shares at an exercise price of $15.36 per share, expiring on May 14, 2036, with 25% vesting on May 15, 2027 and the rest vesting in 36 equal monthly installments.
NeuroPace Inc reported that Chief Medical Officer Martha Morrell received new equity awards. She acquired 5,460 shares of common stock in the form of restricted stock units, bringing her direct holdings to 52,743 shares of common stock.
She was also granted a stock option for 14,550 shares of common stock at an exercise price of $15.36 per share, expiring on May 14, 2036. The RSUs and options each vest 25% on May 15, 2027, with the remaining portions vesting over subsequent quarterly and monthly installments, respectively.
NeuroPace Inc CEO Joel Becker reported equity awards consisting of restricted stock units and stock options. He received 45,880 RSU-based shares of common stock, bringing his common stock holdings to 142,817 shares. He was also granted options on 122,190 shares at an exercise price of $15.36, expiring on May 14, 2036.
The RSUs vest 25% on May 15, 2027, with the remainder in twelve equal quarterly installments. The stock options vest 25% on May 15, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.
NeuroPace Inc’s Chief Medical Officer Martha Morrell reported a routine share transfer related to taxes rather than a market trade. On March 24, 2026, 1,341 shares of common stock were withheld by the company at $13.27 per share to cover tax obligations from the vesting of a restricted stock unit award. After this tax-withholding disposition, she directly holds 47,283 common shares, indicating she retains the substantial majority of her equity position. This event reflects standard tax treatment of equity compensation, not an open-market purchase or sale.
Geiger Uri reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Uri Geiger received 913 shares of Common Stock as a grant on March 20, 2026 at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. Following the grant, he holds 14,858 shares directly and an additional 4,432,948 shares indirectly through Accelmed Partners II LP, where he has sole voting and dispositive power over the held shares.
LACOB JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Joseph Lacob received a grant of 865 shares of common stock at $13.00 per share as part of non-employee director compensation in lieu of quarterly retainer fees. Following this award, he holds 14,754 shares directly, plus indirect holdings through Lacob Ventures LLC and LCT18 Investments.
Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Rakhi Kumar received an equity grant of 1,153 shares of Common Stock at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, bringing Kumar’s direct holdings to 19,160 shares.
Fischer Frank M reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Frank M. Fischer received 1,826 shares of Common Stock as a grant at $13.00 per share. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees.
Following this stock compensation, Fischer directly owns 595,177 shares, indicating this was a routine, compensation-related equity award rather than an open-market purchase or sale.
NeuroPace Inc’s chief medical officer Martha Morrell reported two recent stock transactions. On December 15, 2025, she completed an open-market sale of 25,000 shares of common stock at a weighted average price of $15.97 per share under a Rule 10b5-1 trading plan.
On March 3, 2026, 1,340 shares of common stock were withheld to cover tax obligations tied to the vesting of a restricted stock unit award, at a price of $13.83 per share. After these transactions, she directly held 48,624 shares of NeuroPace common stock.
NeuroPace Inc’s CEO Joel Becker reported a tax-related share withholding. On March 3, 2026, 5,023 shares of common stock were disposed of at $13.83 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this withholding, Becker directly owns 96,937 shares of NeuroPace common stock.
NeuroPace CEO Joel Becker reported a tax-related share withholding tied to a restricted stock unit vesting. On February 27, 2026, 1,126 shares of common stock were withheld by the company at $14.58 per share to cover tax obligations. After this tax-withholding disposition, Becker directly owned 101,960 shares.
NeuroPace Inc's chief medical officer reports a small share disposition tied to tax withholding. On February 27, 2026, 358 shares of common stock were withheld at $14.58 per share to satisfy tax obligations from a restricted stock unit vesting, rather than an open-market sale. Following this tax-withholding disposition, Martha Morrell directly held 74,964 shares of NeuroPace common stock.
NeuroPace Inc's Chief Medical Officer, Martha Morrell, reported a tax-related share disposition. On February 20, 2026, 3,412 shares of common stock were withheld by the company at $14.34 per share to cover tax obligations from a restricted stock unit vesting. After this withholding, she directly owned 75,322 shares of NeuroPace common stock.
NeuroPace, Inc. (NPCE) chief medical officer Form 4 filing reports an automatic share withholding related to equity compensation. On 11/20/2025, 3,051 shares of common stock were withheld by the company at a price of $13.50 per share to cover tax obligations tied to the vesting of a restricted stock unit award. After this tax withholding event, the reporting officer beneficially owned 80,429 shares of NeuroPace common stock directly.